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Summary Both lymphokine activated killer (LAK) cells and specific cytotoxic T lymphocytes appear to play
a role in tumour immunity. Tumour infiltrating lymphocytes (TIL) which display a CD56+ phenotype (both
CD3+ and CD3-) are also likely to possess anti-tumour activity. We have previously described a 120 kDa
surface antigen, termed LAK1, expressed on a subset of human peripheral blood lymphocytes (20-50%) with
both NK and LAK activity. The aim of the present study was to determine whether LAKI antigen is able to
distinguish among TIL two populations of effector cells displaying either specific or non MHC-restricted
(NK/LAK) activity. We showed that about 25% of freshly derived TIL were weakly stained with anti-LAKl
monoclonal antibody and most of them were also CD3+CD56-. After culture in recombinant interleukin-2 the
majority of TIL were CD3+CD56- and the percentage of LAK1 + cells increased up to 50%. Among cloned
TIL, only those lacking LAKI antigen displayed a specific cytotoxicity against the autologous tumour,
whereas the non-lytic clones were able to produce both tumour necrosis factor and gamma-interferon.
Moreover, when TIL from a renal cell carcinoma were fractionated into LAK I - and LAKI + populations, the
specific lytic activity was mainly evident when LAKI - lymphocytes were used as effector cells. Conversely,
LAK activity was confined to the LAK1+ subset.
It has been reported that both lymphokine activated killer
(LAK) cells and specific cytotoxic T lymphocytes (CTL) play
a role in tumour immunity (Muul et al., 1987; Belldegrun et
al., 1988). Tumour infiltrating lymphocytes (TIL) derived
from a number of human solid tumours and grown in the
presence of recombinant interleukin-2 (rIL2) were shown to
mediate anti-tumour cytotoxicity in vitro. This cytotoxicity
was reported to be specific for autologous melanomas and
some lung tumours (Muul et al., 1987; Itoh et al., 1988).
Nevertheless other studies failed to confirm the major histo-
compatibility complex (MHC)-restricted killing of fresh
tumour cell targets by IL2-activated human TIL (Belldegrun
et al., 1988; Whiteside et al., 1988). Moreover, TIL bearing
the CD56 antigen (both CD3+ and CD3-) are also likely to
possess anti-tumour activity (Lanier & Phillips, 1986).
It remains unclear which population (T, NK, LAK) is
responsible for anti-tumour immunity and whether or not a
specific antigen recognition (MHC-restricted and T cell
mediated) is required. We have previously described a surface
antigen expressed on a subset of human peripheral blood
lymphocytes (PBL) with both NK and LAK activity (Zocchi
et al., 1987); a fraction (one-third) of LAKI + cells co-
expressed surface markers (CD3 and CD4 or CD8) of the T
cell lineage (Zocchi et al., 1989). On the basis of these
considerations, we investigated whether LAKI antigen is able
to distinguish, among TIL obtained from different tumours,
two populations of effector cells displaying either specific or
non-MHC-restricted cytotoxic activity. We first expanded
TIL from renal and lung tumours, using either low (25 U
ml-') or high (1,000 U ml-') doses of rIL2, and evaluated
the phenotype and function of the two populations. Clonal
analysis of TIL from one patient with renal cell carcinoma
(RCC) was then performed and the clones were tested for the
pattern of lytic activity, the expression of LAKI antigen and
the production of tumour necrosis factor (a-TNF) and
gamma-interferon (y-IFN). Finally, the cytotoxic activity of
unsorted, LAKI + and LAKI TIL from RCC was evaluated
both against fresh autologous or allogeneic tumour targets
and the NK-sensitive cell line K562. We show that after
culture in rIL2 the percentage of LAKI+ TIL increased up
to 50% and the specific lytic activity was confined to the
LAK1- cells (both at the population and at the clonal level).
Conversely, LAKI+ clones did not display any significant
killing but produced high amounts of a-TNF and y-IFN.
Materials and methods
Fresh tumour biopsies were obtained at surgery from six
primary lung tumours and six renal cell carcinomas. Tumour
tissues were digested with enzymes, washed and enriched
either in TIL or tumour cells on Ficoll-Hypaque differential
gradients. Tumour cells were cryopreserved until used. TIL
were cultured in tissue culture medium in the presence of
either 25 U ml-' or 1,000 U ml-' rIL2 (EuroCetus, Amster-
dam).
The surface phenotype was determined by two-colour cyto-
fluorimetric analysis using a fluorescence activated cell sorter
(FACStar, Becton Dickinson, Mountain View, CA, USA).
Briefly, aliquots of 106 cells were stained with the correspond-
ing Fluorescein-isothiocyanate (FITC)-conjugated mono-
clonal antibodies (MoAbs) (anti-CD3 Leu4, anti-CD4 Leu3a,
anti-CD8 Leu2a, anti-CD56 Leul9) or with 0.5 jg of purified
LAKI MoAb (Zocchi et al., 1987) followed by FITC-conjug-
ated goat anti-mouse IgG (Cappel, Cochranville, PA, USA).
Double staining was performed by direct immunofluore-
scence using FITC-Leu4 plus Phycoerythrin (PE)-conjugated
Leul9 MoAbs or indirect immunofluorescence with LAKI
MoAb, FITC-goat anti-mouse IgG2a (Cappel) followed by
PE-Leu4 or PE-Leul9. MoAbs used for staining were pur-
chased from Becton Dickinson, with the exception of anti-
LAKI MoAb. Cytolytic activity was evaluated in a standard
4 h 51Cr release assay using autologous and allogeneic fresh
tumour cells, the NK-sensitive K562 cell line and two NK-
resistant cell lines (Mel 10 and Epa 1) as targets. Lectin-
dependent cellular cytotoxicity (LDCC) was performed with
5 tLg ml-' phyto-haemoagglutinin (PHA, Sigma Chemicals
Co., St Louis, MO, USA) and the P815 murine cell line as
target. All the experiments were performed at different
effector:target (E:T) ratios (from 30:1 to 3:1). The results
were expressed either as lytic units per 106 cells (Henney,
1971) or as percent specific lysis, as follows:
experimental release (c.p.m.) - min. release (c.p.m.) %
max. release (c.p.m.) - min. release (c.p.m.)
Maximum release was determined by lysis of 5'Cr-labelled
target cells in 0.1 N HCI. Minimum release was evaluated by
incubating target cells in culture medium alone.
Cloning of TIL was carried out by limiting dilution
according to Moretta et al. (1983). Briefly, TIL from a renal
cell carcinoma (RCC) cultured for 10 days in 25 U ml1I
rIL2, were seeded (10-0.5 cells per well) in U-bottomed
microwell plates in the presence of irradiated autologous
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splenocytes as feeder cells and 25 U ml1' rIL2. The cloning
frequency, calculated according to Taswell (1981), was 1/3.2,
in keeping with data from other laboratories (Whiteside et
al., 1988). Growing clones were expanded in rIL2 (25 U
ml-') and subsequently tested for phenotype and function.
LAKI+ and LAKI- populations were fractionated by roset-
ting with ox erythrocytes coated with affinity-purified goat
anti-mouse Ig (Ramarli et al., 1987). LAKI+ cells contam-
inating the LAKI+ fractions were less than 3%.
Quantitation of xTNF and y-IFN was performed as pre-
viously described. Briefly, clones were washed twice in RPMI
1640 and cultured for 36 h with 1% Phytohaemoagglutinin
(PHA Sigma Chemicals Co., 10 g ml-' final dilution) at
5 x 104 cells per microwell. Cell-free supernatants (SN) were
collected and tested for y-IFN and a-TNF activity. Gamma-
IFN Units were determined using vescicular stomatitis virus
infected human amniotic (FL) cells in a 50% cytopathic
effect reduction assay (Melioli et al., 1985). Gamma-IFN
titres present in the SN were evaluated as the reciprocal of
the highest dilution giving 50% reduction of the cytopathic
effect in infected control cultures. U ml-' of y-IFN were
calculated in comparison with T-IFN titres of a standard
curve. Alpha-TNF activity was tested evaluating the cyto-
pathic effect of SN from TIL clones on Actinomycin-D
(Sigma) treated WEHI 164 sarcoma cells in a 5'Cr release
assay (Colotta et al., 1985). SN-induced specific lysis of
5'Cr-labelled WEHI 164 cells was compared with lysis
obtained using purified a-TNF (T Cell Sciences Inc., Cam-
bridge, MA, USA). Picograms ml-' of ax-TNF were calculat-
ed on the basis of a standard curve.
Results
Phenotype andfunction ofbulk cultured TIL
TIL obtained from lung and renal tumours grew successfully
in rIL2 independent of the concentration (25 or 1,000 U
ml-') and they were easily expanded over a period of 3-4
weeks. Phenotypic analysis showed that 45% of freshly
derived TIL were CD4+ whereas 27% were CD8+. LAKI
antigen was weakly expressed on about 25% of TIL most of
which (>75%) were also CD3+CD56-. After culture in
rIL2, the percentage of LAKI+ TIL increased to 50%, and
these cells expressed either the CD3 (50-60%) or CD56
(20-30%) molecule. We further evaluated the co-expression
of CD3 and CD56 surface antigens on fractionated LAKI+
and LAKI- cultured TIL. As shown in Figure 1, CD3+
CD56+ cells represented about 35% of LAKI+ TIL (Figure
la) and 17% of LAKI - cells (Figure lb) respectively.
Moreover, TIL cultured in 25 U ml-' rIL2 contained pre-
dominantly CD4+ cells, whereas a higher percentage of
CD8+ lymphocytes was observed in the presence of 1,000 U
ml-' rIL2 (Table I). When the lytic activity of unfractionated
TIL was analysed, using autologous and allogeneic tumours,
and the K562 cell line as targets, a specific cytotoxicity was
observed only in two cases. No significant difference between
low and high doses of the lymphokine in terms of induction
of cytotoxicity against fresh autologous tumours was evident
in most cases; conversely NK activity was constantly higher
after culturing effector cells with 1,000 U ml-' rIL2 (not
shown). We could not detect any relationship between
phenotypic or functional pattern of TIL and their source
(lung or kidney cancer).
Cloning of TIL
To characterise further the effector cells among TIL, clonal
analysis by limiting dilution was carried out, and the growing
clones were analysed with regard to their lytic activity,
lymphokine production and expression of LAKI antigen.
Ten clones (out of 21 tested) did not exert any type of
cytotoxicity whereas eleven clones displayed high lytic poten-
tial in LDCC (Table II). The majority of these clones (9/11)
were LAK1+, six were also CD4+ while four expressed the
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Figure 1 Two-colour cytofluorometric analysis of CD3 (green
fluorescence, x axis) and CD56 (red fluorescence, y axis) antigen
expression on fractionated LAKI+ a, and LAK1- b, TIL. Cells
were fractionated by immunorosetting and stained with
Fluorescein-conjugated anti-CD3 (Leu4) followed by
Phycoerythrin-conjugated anti-CD56 (Leul9) MoAbs and run on
a FACStar Plus.
CD8 antigen and one was CD4-CD8-. Surprisingly, none of
the 11 clones showing LDCC was able to kill the fresh
allogeneic tumour nor the NK-resistant Mel 10 and Epal cell
lines. Conversely, two clones displayed a significant killing of
the autologous tumour and both of them lacked the LAKI
antigen (Figure 2a). It is of note that only one clone, showing
CD3+WT31- phenotype, killed the NK-sensitive K562 cell
line (Figure 2a and Table II). Moreover, we observed that all
LAKI+ TIL clones produced high amounts of both a-TNF
and y-IFN upon stimulation with PHA, whereas the LAK -
did not (Figure 2b).
Fractionation ofLAKIJ and LAKI- TIL
In order to confirm the hypothesis that LAKI antigen might
dissect TIL into specific CTL and NK/LAK cells, TIL from
a RCC were fractionated into LAK1+ and LAK1- cells by
immunorosetting and tested for their lytic activity against
autologous or allogeneic tumour targets and the K562 cell
line. Lysis of the autologous tumour was mainly evident
when LAK1- TIL, cultured both with low and high doses of
rIL2, were used as effector cells. On the other hand LAK
activity was present only when 1,000 U ml-' rIL2 were used,
and was confined to the LAK1 + subset (Table III). As shown756 M. FERRARINI et al.
TableI SurfacephenotypeofTILobtainedfromsixlungandsixkidneytumoursandexpandedinpresence
of rIL2
CD56+ CD3+ CD56+
Days ofculturea CD4+ CD8+ LAK1+ CD56+ LAK1+ LAK1+ CD3+
Day 0 45±6b 27±7 28±7 12±6 4±2 20±7 2±1
Day 7=QIL2 25Uml-' 51±8 29±6 28±5 17±4 6±2 22±6 4±1
Day 7=QIL2 1,OOOUml-' 40±7 39±8 36±6 23±4 9±4 29±6 9±1
Day 14+rIL225Uml-' 52±4 34±5 31±7 15±6 6±2 27±5 11±5
Day 14+rIL2 1,OOOUml 30±6 54±7 46±5 31±6 14±3 34±7 19±6
aCells were cultured up to 14 days in rIL2 at different concentrations. bPercentage positive cells. Mean
values±s.d.
Table II Phenotypic and functional analysis of cloned TIL from a renal cell carcinoma
Surface phenotype Cytolytic activity
CD4+ CD8+ WT31- LAKI+ CD45R+ CDW29+ LDCC NK LAK CTL
14/21a 6/21 1/21 11/21 1/21 20/21 11/21b 1/21 0/21 2/21
aNumber ofpositive clones. bNumber ofclones showinglytic activity (> 20% ofspecific lysis at the E:T
ratio of 10:1).
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Figure 2 Natural killer (NK) vs specific lysis (CTL) (a, %
specific lysis) and production of gamma-interferon (y-IFN) (b,
IU ml-') vs tumour necrosis factor alpha (a-TNF) (b, pg ml-') of
the 11 clones showing LDCC compared with their LAK1
phenotype (LAKI+, 0; LAK1-, *).
in Figure Ib, LAKI- subset was mainly represented by
CD3+CD56- cells, whereas one-third of LAKI + TIL (Figure
la) was CD3+CD56+. These data further suggest that
LAKI+ TIL are enriched in non-MHC-restricted cytotoxic T
lymphocytes bearing NK cell markers (CD56). No significant
difference in terms of NK activity was observed between
LAKI- and LAKI + cells. Similar results were obtained
using TIL from a lung carcinoma (not shown).
Table III Cytotoxic activity of fractionated LAKI+ and LAKI-
TIL
LU per Io' cellsa
Autologous Allogeneic
25 U ml-'
LAK1 + 2.1 5.8
LAKI- 20.5 2.2
1,000 U ml-'
LAKI + 5.2 12.4
LAKI- 66.8 < I
aOne LU was defined as the number of effector cells needed to lyse
20% of5 x I03 targets. Data are referred to TIL from a RCC grown in
the presence of 25 U ml-' or 1,000 U ml- rIL2.
Discussion
The aim of our study was to determine whether LAKI
antigen is able to distinguish among TIL obtained from
different solid tumours, two populations of effector cells with
either specific or LAK activity. We first analysed the distribu-
tion of the LAKl molecule on TIL, and found that about
25% of freshly derived TIL were weakly stained with anti-
LAKI MoAb. As previously reported (Zocchi et al., 1989),
the LAKI antigen showed a bimodal distribution among
normal PBL, defining two subsets of cells with different
reactivity with the MoAb (in terms of fluorescence intensity).
Most brightly stained LAKi + lymphocytes co-expressed the
CD2 and CD56 antigens but lacked CD3, whereas a fraction
(50%) ofweakly stained LAKI + cells co-expressed also CD3.
Since the vast majority of TIL belonged to the T cell lineage,
the finding of a weak reactivity with anti-LAKI MoAb was
consistent with the above mentioned data. After culture in
rIL2 the percentage of LAKI + TIL increased up to 50% and
these cells co-expressed either CD3 (50-60%) or CD56
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(20-30%) antigens (Table I). In addition, among LAKI+
cells, about one-third co-expressed the CD3 and CD56
molecules. As the expression of LAKI antigen is not induced
by rIL2, the increase of LAK1+ cells suggests that under
these culture conditions a population of LAK cells was
expanding. In agreement with this observation, the LAK
activity of TIL cultures, when evaluated at different time
intervals, increased over the following two weeks (not
shown). Moreover, TIL cultured in 25 U ml-' rIL2 contained
predominantly CD4+ cells, whereas a higher percentage of
CD8+ lymphocytes was observed in the presence of 1,000 U
ml-' rIL2. The lytic pattern of cultured TIL was quite
variable and in only two cases (out of 12) was a specific
cytotoxicity observed. We could not detect any significant
difference between low and high doses of rIL2 in terms of
killing of fresh tumour targets, while NK activity seemed to
be dose-related. In these experiments we used two concentra-
tions of the lymphokine in order to rule out the possibility
that high doses could mask any specific lytic activity. No
relationship between phenotypic or functional pattern of TIL
and their source (lung or kidney cancer) was detected.
A clonal analysis of TIL from a RCC showed that the
majority of the clones were CD4+, LAKI+ and displayed
high lytic potential in LDCC (Table II). Nevertheless only
one clone was able to kill K562 target cells and none of the
clones tested killed the allogeneic tumour. Interestingly, the
clone with NK activity showed a CD3+WT31- phenotype
consistent with data from other laboratories supporting the
notion that gamma' delta' T lymphocytes are able to exert
non MHC-restricted cytotoxicity (Borst et al., 1987). Two
clones displayed a slight but significant specific lysis and both
of them were LAKI-. Furthermore, unlike LAKI- clones,
all LAKI' TIL clones produced high amounts ofox-TNF and
y-IFN upon stimulation with PHA (Figure 2b). Recently, it
has been reported that tumour cell lines stimulate LAK cells
to produce factors, in particular y-IFN and TNF, with slow
acting cytotoxic activity (Chong et al., 1989).
LAKI + clones might exert their anti-tumour activity
throughout this mechanism rather than killing tumour targets
by direct cell to cell contact. It is of note that LAKi - clones
did not produce either lymphokine, suggesting that a-TNF
and T-IFN are not responsible for the autologous tumour cell
lysis displayed by these clones. The different capability of
producing a-TNF and 'y-IFN showed by LAKI + and
LAKI- cloned TIL further support the concept that LAKI
antigen could divide TIL into two populations with different
functional properties.
On the basis of these data we were able to hypothesise
that, among TIL, specific cytotoxic lymphocytes were
confined to the LAK1- population, whereas cells expressing
LAK1 antigen were responsible for LAK activity. In order to
substantiate this hypothesis, TIL from a RCC were frac-
tionated into LAKI+ and LAK1- cells and tested for their
lytic activity against autologous or allogeneic tumour targets
and the NK-sensitive K562 cell line. Lysis of the autologous
tumour was mainly evident when LAK1- TIL, cultured with
both low and high doses of rIL2, were used as effector cells.
On the other hand LAK activity was present only when
1,000 U ml1 1 rIL2 were used and was confined to the
LAK1+ subset (Table III). No significant difference in terms
of NK activity was observed among the LAK1 + and LAK1I
subsets (not shown).
On the basis of our results, we conclude that TIL can be
dissected by LAKI MoAb into two subpopulations with
either specific or LAK activity. It is not clear what role these
cells play in the control of tumour growth and metastasis.
Nevertheless, the LAKI MoAb may represent a useful tool
for studying the relationship between T lymphocytes and
tumour cells. Further studies to define cellular and biological
characteristics of TIL, both at the population and at the
clonal level, are in progress.
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